SciSparc announces enrollment of first five patients in clinical trial of its innovative SCI-210 treatment

The clinical trial for SCI-210 is conducted in Israel, after which the company plans to continue the commercialization process of SCI-210, first in the Israeli market

TEL AVIV, Israel, Aug. 19, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a clinical-stage pharmaceutical company focused on the development of therapies for the treatment of central nervous system disorders, today announced that the first five patients have been enrolled and dosed in its ongoing clinical trial in children with autism spectrum disorder (“ASD”) at Soroka Medical Center in Israel.